BACKBEAT trial of AVIM therapy exceeds enrolment goal

Orchestra BioMed Completes Enrollment in Hypertension Trial

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has exceeded its enrollment target in a pivotal hypertension trial conducted with Medtronic, moving the companies toward primary endpoint data …

BACKBEAT trial of AVIM therapy exceeds enrolment goal

Orchestra BioMed has announced that it has surpassed full enrolment in the BACKBEAT global pivotal trial, exceeding its previously announced target of 316 randomised patients. The BACKBEAT trial is evaluating atrioventricular interval modulation (AVIM) therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of medication. The trial is being conducted with Medtronic, the company’s […]